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OBJECTIVE — The purpose of this study was to analyze the economic outcomes of a clinical
program implemented to achieve strict glycemic control with intensive insulin therapy in pa-
tients admitted to the intensive care unit (ICU).
RESEARCH DESIGN AND METHODS — A difference-in-differences (quasi-
experimental) study design was used to examine the associations of an intensive insulin therapy
intervention with changes in hospital length of stay (ICU and total), costs (ICU and total), and
mortality.Hospitaladministrativedatawereobtainedfor6,719adultpatientsadmittedbetween
2003 and 2005 to one of ﬁve intervention or four comparison ICUs in a large academic medical
center. Linear regression models with log transformations and appropriate retransformations
were used to estimate length of stay (LOS) and costs; logistic regressions were used to estimate
mortality.
RESULTS — After adjustment for observable patient characteristics and secular time trends,
theinterventionwasconsistentlyassociatedwithloweraverageglucoselevelsandatrendtoward
shorter LOS, lower costs, and lower mortality. However, associations with resource use and
outcomes were statistically signiﬁcant in only ICU LOS, with an average reduction of 1.19 days
of ICU care per admission. Other associations, although large in magnitude and in the hypoth-
esized directions, were not estimated with sufﬁcient precision to rule out other net effects. The
associations with ICU days and costs were larger in magnitude than total days and costs.
CONCLUSIONS — AclinicalteamfocusedonhyperglycemiamanagementforICUpatients
can be a valuable investment with signiﬁcant economic beneﬁts for hospitals.
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I
ncreasing evidence supports imple-
mentation of intensive insulin therapy
(IIT) in critical illness. Close links be-
tween hyperglycemia in hospitalized pa-
tients and poor clinical outcomes have
beendemonstratedinavarietyofhospital
settings, such as during critical illness, af-
ter cardiothoracic surgery, organ trans-
plant, stroke, and trauma, and even in
general medical wards. Furthermore, in-
terventional studies have demonstrated
signiﬁcant reductions in morbidity and
mortality when illness-related hypergly-
cemia is treated with IIT (1–5). As insti-
tutions strive to achieve better glucose
control for these patients, they are faced
with both clinical and ﬁnancial obstacles.
Although the evidence for clinical
beneﬁts of strict glucose control in hospi-
talized patients with illness-related hy-
perglycemia is mounting, the ﬁnancial
beneﬁts are less well documented. Dia-
betic and nondiabetic patients with hy-
perglycemia have more complications,
resulting in a longer hospital length of
stay (LOS) and higher costs (6,7). In a
retrospective analysis of cardiothoracic
surgery patients with and without diabe-
tes,each50mg/dlincreaseinglucosewas
associated with 0.76 more postoperative
days, $2,824 more inpatient hospital
charges, and $1,769 more inpatient hos-
pital costs (6). In stroke patients, hyper-
glycemia 130 mg/dl on admission was
related to a 1-day longer LOS and $1,349
higher inpatient hospital charges (7).
These increased costs were partially due
to the known complications of hypergly-
cemia, e.g., nosocomial catheter-related
bloodstream infection (8). When one is
accounting for morbidities such as the
need for mechanical ventilation or dialy-
sis, infections, and other complications,
the costs of untreated hyperglycemia
could be substantial.
Therefore, intensive treatment of hy-
perglycemia may reduce morbidity,
which can translate to reductions in hos-
pital LOS and costs. In fact, the few stud-
iesofIITtreatmentthatincludedﬁnancial
analysis have shown signiﬁcant cost re-
ductions. A post hoc analysis of the Dia-
betesMellitusInsulin-GlucoseInfusionin
Acute Myocardial Infarction (DIGAMI)
trial, in which patients with diabetes and
myocardial infarction were randomly as-
signed to intensive versus conventional
glycemiccontrol,estimatedthatIITsaved
€16,900 per life-year gained (9). Simi-
larly, a post hoc ﬁnancial analysis of the
2001 Van den Berghe trial of surgical in-
tensive care unit (ICU) patients demon-
strated a cost savings of €2,638 per
patient in the IIT group (10). Finally, a
before and after design of patients admit-
tedtoonemixedmedical-surgicalICUes-
timated that IIT decreased ICU LOS by
0.3 days and resulted in a cost savings of
$1,580 per patient for the entire hospital-
ization (11).
Although suggestive that IIT resulted
in hospital cost savings, these studies
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guish effects of the intervention from sec-
ular time trends in hospital LOS, costs,
and mortality, hence potentially con-
founding the estimated intervention ef-
fect. Moreover, only the last study was in
a U.S. health care system. We sought to
addresstheselimitationsbyusingaquasi-
experimental study design to report the
outcomes of a program dedicated for IIT
in ICU patients at an academic U.S. med-
ical center. Measures examined included
mean glucose values, ICU LOS, total hos-
pital LOS, ICU costs, total hospitalization
costs, and inpatient mortality.
In January 2005, UCLA initiated a
new clinical program, TRIUMPH (TaR-
getedInsUlintherapytoiMProveHospital
outcomes). The goal was to achieve strict
glucosecontrolinaccordancewiththeev-
idence-based practice supported by
American College of Endocrinology
guidelines (12). Because UCLA has nine
different ICUs, each with specialized pa-
tient populations, the program was im-
plemented in several phases. Thus far,
ﬁve of the nine ICUs have received the
TRIUMPH intervention including the
medicalintensivecare,coronarycare,and
cardiothoracic surgery units. These units
were chosen on the basis of previously
published beneﬁts in these patient popu-
lations (1–6). Medical directors of these
units were offered the intervention, and
all of them willingly participated. The
units that did not receive intervention in-
cluded liver transplant, neurosurgery,
trauma, and other postsurgical units.
A multidisciplinary approach was
used to develop new insulin therapy pro-
tocolsandeducatethephysicians,nurses,
pharmacists, and dietitians. The intrave-
nous insulin therapy protocol was a mod-
iﬁed version of the Markovitz protocol
(13),andthesubcutaneousinsulinproto-
col incorporated basal, nutritional, and
corrective insulin (14). In the TRIUMPH
units, intravenous insulin infusion was
initiated when the measured glucose was
140 mg/dl. Per the 2004 American Col-
lege of Endocrinology guidelines, the rec-
ommended target glucose ranges were
80–110mg/dlintheICUsettingand80–
110 mg/dl preprandial value with a max-
imal glucose value of 180 mg/dl in the
noncriticalcaresetting(12).Forthecom-
parison units, glucose control was left to
the discretion of those physicians and in-
corporatedbothintravenousinsulininfu-
sions and subcutaneous insulin therapy.
However, these units did not use the TRI-
UMPH protocols and had varied glucose
thresholds and target ranges.
ThecoreTRIUMPHteamconsistedof
an endocrinologist and a diabetes educa-
tortooverseethemanagementofpatients
on a daily basis from admission until dis-
charge. Each patient admitted to an inter-
vention ICU had glucose screening at
regular intervals. If the glucose level was
140 mg/dl and conﬁrmed on a repeat
measurement,theTRIUMPHintravenous
insulinprotocolwasinitiated.Subcutane-
ous insulin was also used when clinically
appropriate.Inmostcases,theTRIUMPH




The study cohort was all patients aged
18 years who were admitted to one of
ﬁveinterventionorfourcomparisonICUs
between 2003 and 2005 and who were
discharged or died in the hospital by 31
December 2005 (n  6,719). The main
analyses included all patients, but sensi-
tivity analyses (n  5,787) excluded
study patients who died before being dis-
charged from the hospital.
To address potential confounding
secular time trends in before and after
comparisons, we used a quasi-experi-
mental or “difference-in-differences”
(DID)approachasdescribedbyGoldman
et al. (15,16). We compared the changes
between the preintervention (2003–
2004) and postintervention (2005) peri-
ods among patients discharged from
intervention units with comparable
changes among patients discharged from
comparison units. Comparable changes
mean that the trajectories over time (i.e.,
the slope of the outcome as a function of
time) should be similar, even if the start-
ing point (i.e., the intercept) is different.
Secular time trends refer to any other
changes that are occurring in the health
care system (or in this hospital in partic-
ular) that would have occurred even in
the absence of the intervention. The DID
estimate takes the average change over
time and subtracts the portion that is
likely to be attributable to secular time
trends and not to the intervention per se.
The validity of the estimated intervention
effect relies on the assumption that (ad-
justing for observable patient characteris-
tics) the underlying time trends in the
outcomeswouldhavebeensimilarforthe
intervention- and comparison-unit pa-
tients in the absence of an intervention.
However, the intervention effect is the
calculated net of the preexisting differ-
ences, thus accounting for the possibility
that the intervention patients may have
startedoffatlowerlevelsofutilizationand
costs. Because this study design accounts
for secular time trends, it implicitly takes
into account factors such as price inﬂa-
tion, changes in hospital-wide ﬁnancial
practices, and ICU procedural changes or
other clinical practices not related to glu-
cose management that can affect LOS,
hospital costs, and mortality.
Outcome measures
Glucose measurements were obtained
from a database consisting of all point of
care testing as well as serum glucose mea-
surements from the laboratory. Hospital
accounting records were used to obtain
information on the total and direct vari-
able costs, total and direct variable ICU
costs, total and ICU LOS, and inpatient
mortality.Totalcostsincludeddirectvari-
able, indirect variable, direct ﬁxed, and
indirect ﬁxed. Direct costs were those
charged speciﬁcally to a revenue-
producing cost center; these costs were
most closely related to providing patient
care. Examples of direct departments are
nursing units, radiology, clinical labora-
tories, and pharmacy. Indirect costs rep-
resent departments that support patient
care rather than provide patient care. Ex-
amples of indirect departments are pa-
tient escort, nutrition, administration,
and ﬁnancial services. Variable costs
change when volume changes, whereas
ﬁxed costs do not change, at least for
small changes in volume.
Although variable costs are the most
relevantintheshortrun,anargumentcan
bemadeforexaminingﬁxedcostsaswell.
From the point of view of a capacity-
constrained medical center, an important
beneﬁt of discharging patients earlier is
the ability to use the beds for new pa-
tients, commonly referred to in hospital
economics as “throughput.” This beneﬁt
is implicitly taken into account when
ﬁxed costs are included in the analysis.
The ﬁxed costs are proxies for the true
“opportunity cost” of the capital (includ-
ing building space), that is, its value for
other uses, such as serving other patients.
Explanatory variables
All regression models included an inter-
ceptandthefollowing:patient’ssex,race,
Latinoethnicity,ageanditssquare,insur-
ance type, indicators for complications
before admission, baseline illness severity
category (calculated by industry standard
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based on Medicare All Patient Reﬁned Di-
agnostic-Related Group system), a linear
time trend for the year of admission, an
indicator for type of unit (intervention
versus comparison), and an interaction
betweenindicatorsforadmissiontimepe-
riod (postintervention versus preinter-
vention) and type of unit. Patients were
assigned to time periods and units based
on their admission date and admission
unit.
The linear time trend allows the out-
come measures to change over time even
in the absence of any intervention, due to
secular trends in length of stay and costs.
The indicator for type of unit allows the
intervention units to start off at higher or
lower levels than comparison units. The
intervention effect is captured by the in-
teractionbetweentimeperiodandtypeof
intervention. For example, if costs in-
crease over time for both the intervention
and comparison units, then the cost in-
creasebetweenthepre-andpostinterven-
tion periods would have to be smaller for
the intervention units than for the control
units to conclude that the intervention
was associated with a cost reduction.
Conversely, if costs decline over time,
then the cost decrease would have to be




ine differences in the demographic and
clinical characteristics of the intervention
and comparison patients. Because of the
skewed distributions of the cost and LOS
measures, these outcomes were log-
transformed in linear regressions, and the
estimates were retransformed to calculate
intervention effects on costs and LOS
measured on the original scales. The re-
gression-adjusted differences in cost and
LOS associated with the intervention
were calculated by predicting the value of
a given outcome Y under four scenarios
(intervention postoutcome, intervention
preoutcome, comparison postoutcome,
and comparison preoutcome) and taking
the DID: [(Yinterv, post  Yinterv, pre) 
(Ycomp, post  Ycomp, pre)] (15). We used
2003 as the preintervention comparison
year, and all other regressors were kept at
theirreportedvalues.Thesamplemeanof
the DID estimate was reported along with
the bias-corrected, empirical 95% CI, de-
rived using 1,000 bootstrap replicates
with replacement (17). Statistical signiﬁ-
cance at the 5% level of type I error was
determined by examining whether the
95% CI excluded 0.
In early analyses, we examined sev-
eral alternative regression speciﬁcations
that allowed more ﬂexibility, e.g., models
allowing each unit to have its own inter-
cept. The speciﬁcations yielded ﬁndings
consistentwiththeﬁnalspeciﬁcation,but
because of concerns about overﬁtting and
interpretability of the results, the most
parsimonious speciﬁcation was ulti-
matelychosen.Wealsoperformedoutlier
analysis to see whether patients with ex-
tremely high resource use were skewing
the results. Excluding the outliers did not
notably inﬂuence our results, although in
the end, we used log transformations for
skewedoutcomestoobtainmoreefﬁcient
estimates. Finally, we estimated random
effects models to determine whether the
conclusions were sensitive to possible
clustering, i.e., within-unit correlation of
the error terms. The intraclass correlation
wasverylow,andourconclusionsdidnot
change on the basis of these estimates.
RESULTS
Changes over time in the case mix of
intervention versus comparison
patients
We ﬁrst examined the changes in ob-
served patient case mix between the pre-
and postintervention periods (Table 1).
The rate of having any complications at
admissiondeclinedfrom4.1to2.3%over
time within patients treated in the com-
parison units (P  0.01). Although the
rate also declined among patients treated
in intervention units (from 4.7 to 4.0%),
the change was smaller and not signiﬁ-
cant. The only other signiﬁcant change
wasaslightincreasebetweenthepre-and
post-intervention periods in the propor-
tion of comparison-unit patients with
Medi-Cal insurance (P  0.03).
Whether the patient had complica-
tions at admission was controlled in the
regressions so this measure itself should
not bias the comparisons. On the other
Table 1—Characteristics of study population by intervention status
Characteristic













n 2,167 1,058 2,406 1,088
Age (years) 61.2  17.0 61.1  17.6 0.85 54.7  17.3 54.1  17.4 0.29
Female sex 38.4 39.4 0.59 43.8 42.1 0.34
Latino ethnicity 13.7 11.2 0.06 21.1 22.1 0.49
Race
Caucasian 82.4 79.9 0.08 79.8 79.9 0.94
African American 6.5 7.8 0.16 7.5 7.0 0.60
Asian 7.7 8.3 0.55 8.9 8.4 0.61
Other 3.4 3.7 0.69 3.8 4.1 0.62
Insurance
Contract/capitated 41.8 43.4 0.39 53.5 51.8 0.35
Medicare 46.2 45.0 0.52 29.3 26.8 0.13
Medi-Cal 7.3 7.7 0.67 8.3 10.6 0.03
Other 4.7 3.9 0.31 8.8 10.7 0.07
Complications at admission 4.7 4.0 0.37 4.1 2.3 0.01
Medical illness severity score 3.17  0.86 3.24  0.84 0.07 3.12  0.98 3.14  0.94 0.63
Data are means  SD or %.
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over time among the comparison patients
than among the intervention patients
could mean that the comparison patients
were becoming relatively healthier over
timeinwaysthatwerenotcapturedbyour
data. If so, then our study design may
yield a conservative estimate of the inter-
vention effects.
Glucose measurements in the
intervention and comparison units
The mean glucose value for each patient
admitted in each unit was calculated for
the years 2004 and 2005. Only one pre-
intervention year, 2004, was used owing
to the very large number of measure-
ments. It was assumed that the year 2003
did not differ from 2004 because the clin-
ical practice of glucose control was not
different. In addition, any bias would
have been in the favor of the comparison
unitsbecausethepracticeofstrictglucose
control was gaining more attention in
theseyearsevenintheabsenceofaformal
intervention. The reduction in mean glu-
cose between the pre- and postinterven-
tion year was 21.5 mg/dl in the
intervention units. In the comparison
units, the difference in mean glucose was
2.3 mg/dl. Regression models looking at
associations of the intervention with
changes in blood glucose during the pa-
tient stay using the same quasi-
experimental study design also showed
large intervention effects.
Unadjusted associations of the
intervention with outcomes
The DID study design relies on the as-
sumption that the time trends that would
have occurred in the absence of any inter-
vention are similar for the intervention
and comparison patients. To examine the
validityofthisassumption,weplottedthe
unadjusted changes in the outcome mea-
sures during the preintervention period
(2003–2004) separately for intervention
versus comparison patients (Fig. 1a–g of
the online appendix [available at http://
dx.doi.org/10.2337/dc07-2456]). Over-
all, the preintervention time trends
looked similar for the intervention and
comparisonpatients.Wheretheydidnot,
the preintervention trends looked worse
for the intervention patients, e.g., LOS
and costs increased more rapidly over
time and the mortality rate increased in-
stead of declining. Therefore if anything,
we expect that the DID estimate would
suggest smaller intervention effects than
the actual improvements in outcomes as-
sociated with the intervention, i.e., a con-
servative bias.
Regression-adjusted associations of
the intervention with the outcomes
After adjusting for observable patient
characteristics and confounding time
trends using the DID approach, the inter-
vention was consistently associated with
lower resource use and better outcomes.
However, the associations were statisti-
callysigniﬁcantonlyintheICULOS,with
an average reduction of 1.19 days of ICU
care per admission (column 2, Table 2).
Not surprisingly, the associations of the
intervention with direct variable cost
were smaller in magnitude than its asso-
ciations with the total cost measures. In-
terestingly, the magnitudes of the
associations with the intervention were
largerforICUdaysandcoststhanfortotal
LOSandcosts,suggestingthatanincrease
in non-ICU utilization might have par-
tially offset the decline in ICU use. The
one statistically signiﬁcant association,
that of the intervention with ICU days,
was quite large in magnitude. To put the
magnitudeofthereductioninICULOSof
1.19 days into context, the baseline mean
ICU LOS of the entire intervention units
group was 9.53 days (SD  16.74).
Excluding patients who died before
discharge yielded associations that were
smaller and not statistically signiﬁcant
(column 3, Table 2). The resource use of
the deceased patients was much higher
than that of the nondeceased patients.
The intervention was associated with an
absolute reduction of 1.1% in mortality,
comparedwithabaselinemortalityrateof
14%. Even though this association did
not reach statistical signiﬁcance, it ex-
plains why the intervention effects on
costs are greater when the deceased pa-
tients are included.
CONCLUSIONS — Using a DID (or
quasi-experimental) study design to ac-
count for the potential confounders in-
herentinpre-postcomparisons,wefound
that a multidisciplinary approach to in-
tensive glucose management of critically
ill patients resulted in greater reductions
in mean glucose values, whereas compar-
ison patients had essentially no change in
mean glucose from the year before to the
year after the intervention was intro-
duced. The intervention was also associ-
ated with a trend toward lower mortality
and lower resource use such as ICU and
total inpatient days and all cost measures
examined. Statistical signiﬁcance was
conﬁnedtotheassociationwithICUdays,
but the effects on other outcomes were all
in the same direction and large in magni-
tude (e.g., a reduction of $5,231 in total
ICU costs). These results suggest that the
interventionmighthavehadabroaderin-
ﬂuence, but that high variability in the







Total costs $4,746 ($10,509 to $1,832) $2,957 ($8,347 to $2,692)
Direct variable costs $2,210 ($5,593 to $1,584) $1,179 ($4,409 to $2,056)
Total ICU costs $5231 ($13,775 to $3,591) $2948 ($11,184 to $5,500)
Direct variable ICU costs $1143 ($4,096 to $2,068) $426 ($3,305 to $2,589)
Total days 0.47 (1.87 to 1.02) 0.31 (0.87 to 1.74)
ICU days 1.19 (1.93 to 0.43)* 0.73 (1.48 to 0.11)
Mortality 0.011 (0.05 to 0.03) —
Data are means (95% empirical, bias-corrected bootstrapped CI) of the DID estimate. Estimates are based on a linear regression with log transformation and
appropriate retransformation algorithm (ref. 18). All regressions control for the patient characteristics shown in Table 1, as well as for a squared age term, a linear
time trend, an indicator for type of unit (intervention versus comparison), and an interaction between indicators for time period (postintervention versus
preintervention) and type of unit. *Signiﬁcant at P  0.05.
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measure them with sufﬁcient precision.
Although we accounted for obvious costs
related to delivering IIT such as increased
nursing effort, glucose monitoring sup-
plies, and insulin in the direct cost analy-
sis, our current database did not allow us
to identify speciﬁc components of clinical
care that may be directly related to the
observed savings in LOS and costs. This
would undoubtedly be a useful area for
future research. Effect sizes for the utili-
zation and cost measures were reduced
when patients who died (who tended to
be more expensive) were excluded from
the sample, suggesting that the effect of
theinterventiononinpatientresourceuse
resulted in part from helping to keep pa-
tients alive, at least until discharge. This
study is subject to certain limitations.
Most notably, the intervention was stud-
iedinasingleacademicmedicalcenter,so
results may not apply to other settings.
Patients whose stays occurred in part be-
fore the intervention and in part after the
intervention were assigned to the prein-
tervention period. This measurement error
may bias our estimates in a conservative di-
rection. In the intervention units, IIT was
implemented by the TRIUMPH clinical
service under formalized protocols. The
comparisonunitsalsousedinsulinther-
apy at the discretion of the physician,
but this was done on an individual basis
and without the TRIUMPH protocols.
However, this crossover should only
lead to a conservative bias of our out-
comes.
Our DID study design also relies on
the assumption that the secular time
trends affecting the intervention and
comparison units are similar. If this as-
sumption fails, then our estimates may be
misleading. For example, if inﬂation in-
creased costs in the comparison units to a
greater degree than that in the interven-
tion units, then we might overstate the
association of the intervention with re-
ductions in costs (although inﬂation per
se would not affect associations with
LOS). However, graphs of the preexisting
time trends suggest that if anything, the
opposite was probably true, i.e., that the
intervention units had worse trajectories
ofchangeovertime,andthereforetheim-
provement in outcomes after the intro-
duction of the intervention represented
an even greater achievement. In any
event, this DID assumption should be
more valid than that of earlier pre-post
study designs that did not take secular
time trends into account at all.
We calculated a potential ICU cost
savings of $5.5 million in the group of
patients treated by the TRIUMPH team in
the ﬁrst year after the implementation of
theintervention.At$5.0million,thetotal
cost savings was slightly less than ICU
costs, but nevertheless substantial. The
costs of setting up the program that were
not already included in the analysis were
limited to the salaries of a full-time endo-
crinologist and a diabetes educator. The
costs of delivery of care (e.g., insulin, glu-
cose meters and strips, and nursing time)
were already included in the cost mea-
sures. Thus, the potential savings associ-
ated with the intervention appear to far
outweigh the costs. As technological ad-
vancesaremadeintheareasofautomated
electronic protocols, continuous glu-
cose sensors, and insulin infusion de-
vices, the costs of implementation may
be even less. Furthermore, as physician
extenders such as nurse practitioners
and physician assistants are used to ex-
pand the service to treat larger numbers
of ICU patients, the investment in the
program will be small in comparison to
the potential savings.
Ourﬁndingssuggestthathospitalad-
ministrators should seriously consider
implementingadedicatedprogramforin-
tensive glucose management in the ICU.
As more knowledge is gained about the
beneﬁts of glucose control among non–
critically ill patients, these programs
might be expanded to this population as
well.Theper-patientcostsavingsmaynot
be as impressive in this group, but the
larger numbers of patients may allow the
intervention to have a signiﬁcant impact
on hospital economics (19,20). Further
investigation is needed to determine the
level of glucose control that is most ben-
eﬁcial in these patients and how the glu-
cose management program can be
tailored to ensure a favorable return on
investment.
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